Making it Possible

Envision a world where progressive myopia is a thing of the past.

With our transformative microdosing technology, we are developing a treatment for progressive myopia, a condition which is associated with several back of the eye diseases and may result in visual disability.

Making it Possible

Envision a world where progressive myopia is a thing of the past.

With our transformative microdosing technology, we are developing a treatment for progressive myopia, a condition which is associated with several back of the eye diseases and may result in visual disability.

Latest News

Eyenovia to present at two upcoming investor conferences

NEW YORK, Sept. 03, 2019 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer and John Gandolfo, Eyenovia’s Chief Financial Officer, are scheduled to present at the 21st Annual H.C. Wainwright 21stAnnual Global Investment Conference being held on September 8-10, 2019 and the Ladenburg Thalmann 2019 Healthcare Conference being held on September 24, 2019 in New York.  Read More

A Transformative Biopharmaceutical Company

Eyenovia is a clinical stage, ophthalmic biopharmaceutical company that is transforming therapies for the treatment of progressive myopia, ocular hypertension and glaucoma, eye puritis and redness, and improving diagnostic eye exams. We believe our breakthrough technology enables these first-in-class microdosed therapies that are designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing drugs.

See How We Make it Possible

Milagro 428px

Milagro

MILAGRO, our phase III NDA-enabling study for elevated IOP (glaucoma) is scheduled to enroll later this year. More Information coming soon!

These results showed the efficacy and safety of the fixed combination microdose formulation and the potential for offices to improve their patient flow. Eyenovia expects to file the NDA for its MicroStat product in 2020.

Close Menu